Cargando…
Clinical holds for cell and gene therapy trials: Risks, impact, and lessons learned
The recent increase in cell and gene therapies being developed has been coupled with a disproportionate increase in Food and Drug Administration (FDA)-mandated clinical holds. Aiming to better understand causes and secondary effects of these clinical holds on biotechnology companies, we analyzed 33...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597781/ https://www.ncbi.nlm.nih.gov/pubmed/37886603 http://dx.doi.org/10.1016/j.omtm.2023.101125 |